Table 3 Baseline characteristics of studies in the prediction field of prostate cancer
No. | Study ID | Years | Country | Prediction task | Number of centers | Number of patients | AI methods | Clinical assessment methods | Comparison# |
|---|---|---|---|---|---|---|---|---|---|
1 | Yan et al. [57] | 2021 | China | BCR | 3 | 485 | HC, DL(2D) | CAPRA-S/NCCN/GGG | > |
2 | Hou et al. [58] | 2021 | China | ECE | 2 | 849 | DL(2D) | Expert reader | > |
3 | Xu et al. [95] | 2020 | China | ECE | 1 | 95 | HC | Clinical and pathological characteristics†| > |
4 | Ma et al. [96] | 2019 | China | ECE | 1 | 210 | HC | Reader | > |
5 | Bai et al. [97] | 2021 | China | ECE | 2 | 284 | HC | Clinical characteristics†| < (internal) ≈ (external) |
6 | Bourbonne et al. [98] | 2021 | France | LNI | 1 | 280 | HC, DL(2D) | Partin/Roach/Yale/MSKCC/… | > |
7 | Hou et al. [99] | 2019 | China | LNI | 1 | 248 | HC | MSKCC | > |
8 | Hou et al. [100] | 2021 | China | LNI | 2 | 401 | HC, DL(2D) | MSKCC/Briganti/… | > |
9 | Li et al. [101] | 2021 | USA | AP, BCR | 4 | 198 | HC | CAPRA/Decipher/CAPRA-S | >/≈ |
10 | Bourbonne et al. [102] | 2020 | France | BCR | 2 | 195 | HC | Clinical characteristics†| > |
11 | Sushentsev et al. [103] | 2022 | UK | Progressing | 1 | 64 | HC | PRECISE | ≈ |
12 | Xie et al. [104] | 2021 | China | Upgrade | 1 | 59 | HC | Biopsy | > |
13 | Zhang et al.[105] | 2020 | China | Upgrade | 1 | 166 | HC | Clinical characteristics†| > |
14 | Wu et al. [106] | 2017 | China | Upgrade | 1 | 46 | HC | Clinical characteristics†| > |
15 | Zheng et al. [107] | 2021 | USA | Biopsy results | 1 | 330 | HC | PSA density†| > |
16 | Wang et al. [108] | 2018 | China | Organ-confined Pca | 1 | 541 | HC | Partin | > |